Massive european study aims to unlock secrets of rare kidney disease
NCT ID NCT05927467
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 700 people with Alport syndrome, a rare inherited disease that can lead to kidney failure, hearing loss, and eye problems. Researchers will collect health data and samples over time to map how the disease progresses and to find early markers of kidney decline. The goal is to better understand the disease and prepare for future treatment trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal early warning signs of kidney failure in Alport syndrome, helping doctors start treatments sooner and guiding the design of future drug trials.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly improve health, and results may take years to produce clear findings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
RaDiCo Eurbio-Alport
RECRUITINGParis, Île-de-France Region, 75012, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to plug kidney leaks in multiple diseases
- Study links gum health to rare kidney diseases
- Alport patients needed: join a registry to speed up research
- Kidney hope: drug combo may slow alport disease
- New drug aims to slow kidney damage in rare alport syndrome
- Experimental drug targets genetic cause of alport syndrome in tiny pilot